Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

Background: Relapsed/refractory acute lymphoblastic leukemia (ALL) remains a major clinical challenge. We have previously shown that relapsed leukemias frequently carry RAS-pathway activatingmutations that could be targeted by MEK-inhibitors in combination with glucocorticosteroids. Methods: Based o...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Britta Vormoor, Joshua Savage, Caroline Kristunas, Sarah Johnson, Mauricio Nicolás Ferrao Blanco, Geoff Shenton, Donna Lancaster, Anna Castleton, Adele K. Fielding, Anne-Louise Latif, Nick Morley, Marion Strullu, Ruta Tuckuviene, Pamela Kearns, Claire Jennings, Shelby Barnett, Gareth J. Veal, Julie Irving, Lucinda Billingham, Tobias Menne, Josef Vormoor
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-06-01
Σειρά:	EJC Paediatric Oncology
Θέματα:	Relapsed/refractory acute lymphoblastic leukemia Phase I/II clinical trial MEK inhibitor Selumetinib Dexamethasone RAS-pathway activating mutations
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2772610X26000085
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!